Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma

This study evaluates whether a cream called imiquimod (IMQ) can effectively treat a type of low-risk skin cancer called basal cell carcinoma (BCC) — the most common type of skin cancer. Researchers want to see how the cream performs in real-world practice and whether advanced imaging (called OCT, a type of non-invasive skin scan) can help diagnose and monitor treatment without requiring a biopsy. **You may be eligible if...** - You are 18 or older with a confirmed low-risk basal cell carcinoma - Your tumor meets specific criteria for low-risk classification - You can understand and follow the treatment instructions **You may NOT be eligible if...** - Your tumor is located on high-risk areas like the center of the face, scalp, or genital area - You have recurrent BCC or another skin cancer nearby - Your BCC is a more aggressive or high-risk subtype - You are pregnant or breastfeeding - You have an allergy to imiquimod - You are taking immunosuppressive medications Talk to your doctor to see if this trial is right for you.